Navigation Links
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

SAN DIEGO, May 15, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational new biologic, in combination with gemcitabine for treatment of patients with stage IV metastatic pancreatic cancer will be presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

In this Phase 1b study, 28 stage IV pancreatic ductal adenocarcinoma patients were treated with PEGPH20 in combination with gemcitabine. The overall response rate (CR+PR) was 42 percent* (n=24) as assessed by independent review at therapeutic dose levels of PEGPH20 (1.6 and 3.0 µg/kg). Treatment was generally well tolerated and the adverse event profile was consistent with those seen in previous studies of PEGPH20 as a single agent and as previously reported for gemcitabine alone. There was no evidence of new observed toxicity. Detailed clinical data, including CA 19-9 and pharmacodynamic results will be presented at the meeting.

Emerging data show that most pancreatic cancers surround themselves with a protective hyaluronan-rich matrix, which makes the disease difficult to treat and is itself an indicator of poor prognosis. PEGPH20 depletes this matrix component from the tumor and rapidly changes the tumor microenvironment and metabolism, which may render it more vulnerable to therapy as well as inhibit tumor growth.

"Data from this single arm Phase 1b study clearly reinforce the hypothesis of treating pancreatic cancer with PEGPH20 in conjunction with chemotherapeutic agents," said Joy Zhu , M.D., Ph.D., Vice President, Oncology Clinical Development,
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... This is a professional and in-depth ... Resin industry in Global and China.The report provides ... applications and industry chain structure. Global market analysis ... a focus on history, developments, trends and competitive ... international and Chinese situation is also offered. , ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Erlab ... laboratory personnel since 1968 and Burdinola, supplier of laboratory ... a new filtered fume hood. , By ... fume hood, Burdinola will now offer an innovative solution ... wide range of chemicals, best-in-class detection technology, and communication ...
(Date:9/23/2014)... Proove Biosciences , the commercial and research leader ... association between specific genes and patients’ predisposition to anxiety ... Congress’ 27th Annual Scientific Program in Orlando, Florida. ... ‘Embracing Change.’ Mental health, and healthcare as a whole, ... presented by the Affordable Care Act to the growing ...
(Date:9/23/2014)... , Sept. 23, 2014 Research ... "Proteomics Markets for Research and IVD Applications ... report to their offering. ... proteomics applications, both in their research use and ... including the study of the structure and function ...
Breaking Biology Technology:Phenolic Resin Industry (International, China) Development Policy and Plan Now Available at ReportsnReports.com 2Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2Proove Biosciences Will Be Exhibiting New Genetic Research at the 27th Annual US Psych Congress Scientific Program 2Proove Biosciences Will Be Exhibiting New Genetic Research at the 27th Annual US Psych Congress Scientific Program 3Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 2Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 3Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 4
... Md. and BEIJING, Jan. 10, 2012 The global ... as Aeras and the China National Biotec Group (CNBG) ... develop new tuberculosis (TB) vaccines. The agreement between the ... largest biotechnology corporation in China signals a commitment by ...
... A superlens would let you see a virus in a drop ... It might, says Durdu Guney, make ultra-high-resolution microscopes as commonplace as ... a superlens, also known as a perfect lens, though people are ... so-called diffraction limit, so even the best won,t usually let us ...
... . , Scientists at Universidad Carlos III ... have joined efforts to develop new materials for thermonuclear ... oxide dispersion-strengthened, reduced-activation steel for the reactor structure. , ... the current energy crisis. It is produced when ...
Cached Biology Technology:Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D 2Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D 3Almost perfect: A breakthrough in superlens development 2New material for thermonuclear fusion reactors 2New material for thermonuclear fusion reactors 3
(Date:9/23/2014)... whose turn it is to do the washing up, negotiating ... as many students returning to university for the new ... a house can be a tricky business. , And now ... that new technology to allow people to monitor their energy ... the tension. , The study by a team of technology ...
(Date:9/23/2014)... California , 23 de septiembre de ... lanzamiento del Sistema 1290 Infinity II LC, ... de Infinity en su portafolio de cromatografía ... científicos y directores de laboratorio que alcancen ... excepcional, facilidad de uso y capacidad de ...
(Date:9/22/2014)... 2014 A new American Cancer Society study suggests ... (SNAP), previously known as the food stamp program, ... eligible non-participants. The authors say the findings emphasize ... the dietary quality of SNAP participants. , The ... households with the resources to obtain a nutritionally ...
Breaking Biology News(10 mins):Smart meters could cause conflict for housemates, study shows 2Smart meters could cause conflict for housemates, study shows 3Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 2Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 3Federal food program puts food on the table, but dietary quality could be improved 2
... by the Smithsonian Institution has completed a new study ... a 3-foot-tall, 18,000-year-old hominin skeleton, discovered four years ago ... one of the most striking confirmations of the original ... one of the oldest human migrations to Asia. The ...
... 20, 2007) Fifteen students mentored by members of the ... receive the 2007ASPB Summer Undergraduate Research Fellowships (SURF). The ... to his or her research project for a 10-week ... to the mentor for lab supplies, a free student ...
... virus first struck New York City in 1999, news ... health officials alike, showing that even affluent, urban societies ... has been widely studied, there is still little known ... urban and rural areas. Assistant professor at the ...
Cached Biology News:New research sheds light on 'Hobbit' 2ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 2ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 3UGA Odum School of Ecology professor receives grant to study West Nile Virus in NYC 2
Human LAIR2 Biotinylated Affinity Purified PAb...
... The mycobacteria in Complete Freund's ... the injection site which enhances the immuneresponse. ... is used for the initial injections; Incomplete ... boosts. Antigens (preferably in saline) are typically ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
Alexa Fluor 350/488/594 Filter Set (Semrock Brightline) *mounted* *Zeiss Axio AF...
Biology Products: